aTyr Pharma Inc Share Price Nasdaq
Equities
US0021201035
Biotechnology & Medical Research
Sales 2024 * | 2.16M 180M | Sales 2025 * | 9.26M 772M | Capitalization | 109M 9.06B |
---|---|---|---|---|---|
Net income 2024 * | -62M -5.17B | Net income 2025 * | -68M -5.67B | EV / Sales 2024 * | 50.3 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 11.7 x |
P/E ratio 2024 * |
-1.61
x | P/E ratio 2025 * |
-1.79
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.38% |
Latest transcript on aTyr Pharma Inc
Managers | Title | Age | Since |
---|---|---|---|
Sanjay Shukla
CEO | Chief Executive Officer | 52 | 30/16/30 |
Jill Broadfoot
DFI | Director of Finance/CFO | 63 | 30/18/30 |
Lisa Carey
CTO | Chief Tech/Sci/R&D Officer | - | 01/15/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Schimmel
FOU | Founder | 83 | 08/05/08 |
Tim Coughlin
CHM | Chairman | 57 | 10/17/10 |
John Clarke
BRD | Director/Board Member | 70 | 01/05/01 |
1st Jan change | Capi. | |
---|---|---|
+25.69% | 48.09B | |
+46.90% | 40.62B | |
-3.46% | 40.43B | |
-6.20% | 28.36B | |
+9.17% | 24.89B | |
-20.42% | 19.01B | |
+28.07% | 12.09B | |
+0.17% | 11.88B | |
-1.24% | 11.8B |